ID   iOvCa241
AC   CVCL_VQ44
DR   cancercelllines; CVCL_VQ44
DR   Wikidata; Q94319943
RX   DOI=10.14288/1.0319145;
RX   PubMed=27822414;
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=27822414).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=27822414
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 12,14
ST   D21S11: 32.2
ST   D5S818: 12
ST   D7S820: 8,10
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C105556; Low grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 7
//
RX   DOI=10.14288/1.0319145;
RA   Dawson A.;
RT   "Targeted therapy in low-grade serous ovarian carcinoma:
RT   characterization of MEK inhibitor response in novel patient-derived
RT   cell lines.";
RL   Thesis PhD (2016); University of British Columbia; Vancouver; Canada.
//
RX   PubMed=27822414; PMCID=PMC5088288;
RA   Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S.,
RA   Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M.,
RA   Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.;
RT   "Differences in MEK inhibitor efficacy in molecularly characterized
RT   low-grade serous ovarian cancer cell lines.";
RL   Am. J. Cancer Res. 6:2235-2251(2016).
//